Compare Ecolab Inc. (ECL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Viatris Inc — how do they compare? Ecolab Inc. trades at $282.15 (market cap $78.97B), while Viatris Inc trades at $17.35 (market cap $20.03B). The key difference: Ecolab Inc. is far larger — about 3.9× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Viatris Inc for 57 Days on average.
| ECL | VTRS | |
|---|---|---|
Market Cap | $78.97B | $20.03B |
Volume | 974,947 | 14,109,977 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $18.27 |
52-Week Low | $245.73 | $9.74 |
Typical Hold Time | 90 Days | 57 Days |
Enterprise Value | $87.75B | $32.15B |
Dividend Yield | 1.04% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $278.10, down 0.97% on the day, with strong analyst support (78% buy ratings) and a $326.38 consensus price target suggesting 17% upside. The stock shows bullish technical signals with support at $275 and resistance at $279. Recent Q2 2026 earnings beat expectations with 9.7% sales growth, while the company maintains dividend aristocrat status with consistent payout increases.
ECL presents a compelling growth story with expanding high-tech and digital segments, though elevated valuation multiples (P/E 37.81) and rising debt from the CoolIT acquisition warrant caution. The essential nature of its hygiene and water management services provides defensive characteristics, while upcoming Q3 earnings on October 27 will be critical for validating growth trajectory.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
